These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 28049184)
1. Binding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity. Liu Z; Liu G; Zhang GL; Li J; He YQ; Zhang SS; Wang Y; He WY; Cheng GH; Yang X; Xu J; Wang J Oncotarget; 2016 Oct; 7(42):68473-68488. PubMed ID: 28049184 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a recombinant soluble ectodomain of mutant human fibroblast growth factor receptor-2 IIIc. Wang J; Liu XT; Huang H; Xiao G; Zhou ZY; Chen Y; Yu ZH; He SL; Chen AA; Wang DD; He Y; Zhang ZC; Hong A Mol Cancer Ther; 2011 Sep; 10(9):1656-66. PubMed ID: 21750221 [TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of msFGFR2c on the epithelial-to-mesenchymal transition of AE2 cells in pulmonary fibrosis. Jieming G; Liu C; Yang Y; Mo S; Yang X; Wang J Biotechnol Lett; 2020 Jun; 42(6):1061-1070. PubMed ID: 32130565 [TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells. Matsuda Y; Hagio M; Seya T; Ishiwata T Mol Cancer Ther; 2012 Sep; 11(9):2010-20. PubMed ID: 22778155 [TBL] [Abstract][Full Text] [Related]
5. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Ruohola JK; Viitanen TP; Valve EM; Seppänen JA; Loponen NT; Keskitalo JJ; Lakkakorpi PT; Härkönen PL Cancer Res; 2001 May; 61(10):4229-37. PubMed ID: 11358849 [TBL] [Abstract][Full Text] [Related]
6. Developmental and hormonal regulated gene expression of fibroblast growth factor 2 (FGF-2) and its receptors in porcine endometrium. Welter H; Wollenhaupt K; Einspanier R J Steroid Biochem Mol Biol; 2004 Mar; 88(3):295-304. PubMed ID: 15120423 [TBL] [Abstract][Full Text] [Related]
7. Discovery and Characterization of a High-Affinity Small Peptide Ligand, H1, Targeting FGFR2IIIc for Skin Wound Healing. Zhao Y; Wang Q; Jin Y; Li Y; Nie C; Huang P; Li Z; Zhang B; Su Z; Hong A; Chen X Cell Physiol Biochem; 2018; 49(3):1033-1048. PubMed ID: 30196288 [TBL] [Abstract][Full Text] [Related]
8. Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2. Billottet C; Janji B; Thiery JP; Jouanneau J Oncogene; 2002 Nov; 21(53):8128-39. PubMed ID: 12444548 [TBL] [Abstract][Full Text] [Related]
9. [Experssion of human FGFR2IIIc and its S252W mutant in MDA-MB-231 breast cancer cells with adenovirus vectors]. Zhang Y; Li L; Chen X; Qin L; Guo S; Liu L; Xu L; Hong A Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):363-70. PubMed ID: 20518350 [TBL] [Abstract][Full Text] [Related]
10. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway. Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884 [TBL] [Abstract][Full Text] [Related]
11. Basic fibroblast growth factor induces VEGF expression in chondrosarcoma cells and subsequently promotes endothelial progenitor cell-primed angiogenesis. Tzeng HE; Chen PC; Lin KW; Lin CY; Tsai CH; Han SM; Teng CL; Hwang WL; Wang SW; Tang CH Clin Sci (Lond); 2015 Jul; 129(2):147-58. PubMed ID: 25735814 [TBL] [Abstract][Full Text] [Related]
12. Fgfr1 and the IIIc isoform of Fgfr2 play critical roles in the metanephric mesenchyme mediating early inductive events in kidney development. Sims-Lucas S; Cusack B; Baust J; Eswarakumar VP; Masatoshi H; Takeuchi A; Bates CM Dev Dyn; 2011 Jan; 240(1):240-9. PubMed ID: 21128305 [TBL] [Abstract][Full Text] [Related]
13. Heparin modulates the mitogenic activity of fibroblast growth factor by inducing dimerization of its receptor. a 3D view by using NMR. Nieto L; Canales Á; Fernández IS; Santillana E; González-Corrochano R; Redondo-Horcajo M; Cañada FJ; Nieto P; Martín-Lomas M; Giménez-Gallego G; Jiménez-Barbero J Chembiochem; 2013 Sep; 14(14):1732-44. PubMed ID: 23940086 [TBL] [Abstract][Full Text] [Related]
14. A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis. Mori S; Tran V; Nishikawa K; Kaneda T; Hamada Y; Kawaguchi N; Fujita M; Saegusa J; Takada YK; Matsuura N; Zhao M; Takada Y PLoS One; 2013; 8(2):e57927. PubMed ID: 23469107 [TBL] [Abstract][Full Text] [Related]
15. Different abilities of the four FGFRs to mediate FGF-1 translocation are linked to differences in the receptor C-terminal tail. Sørensen V; Wiedlocha A; Haugsten EM; Khnykin D; Wesche J; Olsnes S J Cell Sci; 2006 Oct; 119(Pt 20):4332-41. PubMed ID: 17003104 [TBL] [Abstract][Full Text] [Related]
16. Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. Wang F; Lu W; McKeehan K; Mohamedali K; Gabriel JL; Kan M; McKeehan WL Biochemistry; 1999 Jan; 38(1):160-71. PubMed ID: 9890894 [TBL] [Abstract][Full Text] [Related]
17. FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. Sahni A; Khorana AA; Baggs RB; Peng H; Francis CW Blood; 2006 Jan; 107(1):126-31. PubMed ID: 16160009 [TBL] [Abstract][Full Text] [Related]
18. Scopoletin, an active principle of tree tobacco (Nicotiana glauca) inhibits human tumor vascularization in xenograft models and modulates ERK1, VEGF-A, and FGF-2 in computer model. Tabana YM; Hassan LE; Ahamed MB; Dahham SS; Iqbal MA; Saeed MA; Khan MS; Sandai D; Majid AS; Oon CE; Majid AM Microvasc Res; 2016 Sep; 107():17-33. PubMed ID: 27133199 [TBL] [Abstract][Full Text] [Related]